BioCentury
ARTICLE | Clinical News

Vernalis falls on V3381 data

March 25, 2010 12:47 AM UTC

Vernalis plc (LSE:VER) fell 14p (19%) to 60p on Wednesday after V3381 missed the primary endpoint of significantly reducing mean pain scores from baseline vs. placebo in the Phase IIb IN-STEP trial to treat neuropathic pain due to diabetes. Specifically, V3381 led to a 25% reduction in pain scores from baseline vs. an undisclosed percent reduction for placebo. The international trial enrolled 271 patients into a 2-week placebo run-in period, after which 162 patients were eligible to receive up to 400 mg V3381 or placebo for 13 weeks in the treatment phase of the trial. ...